Navigation Links
Discuss Early Results of the DIAN Trial at CBI's 6th Annual Alzheimer's Drug Development Summit
Date:8/21/2012

WOBURN, Mass., Aug. 21, 2012 /PRNewswire/ -- CBI recently added John C. Morris M.D., a Friedman Distinguished Professor of Neurology and Director at Knight Research Center of Washington University School of Medicine, to the prestigious speaker roster for CBI's 6th Annual Alzheimer's Drug Development Summit in Philadelphia.

This December 11-12, attendees come together during the session: Future Perspective from the Dominantly Inherited Alzheimer Network (DIAN) (http://www.cbinet.com/conference/workshop/26087/pc12188) to discuss the early results from the trial as well as review key highlights and information:

  • Analyze the importance of the DIAN trial to Alzheimer's clinical trials
  • Discuss the therapies being evaluated in the DIAN trial and study design
  • Understand the initial results of the DIAN clinical trial and forward goals

With a strong agenda filled with expert speakers reflecting on recent clinical trial implications and current research on translational and preventative treatments for Alzheimer's, CBI's 6th Annual Alzheimer's Drug Development Summit offers industry leaders an educational platform to continue the dialogue of research findings and continue to advance towards the prevention and treatment of Alzheimer's disease.

CBI, an Advanstar company, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators.

Contact: Kristina Weljkovic
Phone number: 339-298-2285
Email address: Kristina.weljkovic@cbinet.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.  


'/>"/>
SOURCE CBI
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AAAS To Host Live Online Discussion On 2013 U.S. Federal R&D Budget
2. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
3. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
4. Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama
5. NIRI San Diego May Meeting: Seasoned IROs Discuss "Tips & Tactics for Establishing and Maintaining A Successful Investor Relations Program"
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Researchers peek at the early evolution of sex chromosomes
8. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
9. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
10. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
11. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , ... in 2020, despite many obstacles created as a result of COVID-19. As a ... its partnered medical practices and medical manufacturers by expanding access to device offerings, ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
(Date:6/23/2020)... ... June 22, 2020 , ... ... DRP-104, will be presented June 22-24 during the American Association for Cancer Research ... the other profiles the potent, consistent single agent activity in KEAP1 mutant tumor ...
(Date:6/11/2020)... ... June 09, 2020 , ... ... of the NEON Micro-Tracer Solution, a highly accurate, contact tracing solution ... in the workplace. Contact tracing, a core disease control measure, is a key ...
Breaking Biology Technology:
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC , ... that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) ... with severe COVID-19. This is the first study of an XPO1 inhibitor in ...
(Date:6/23/2020)... ... June 22, 2020 , ... The field of quantitation of ... assays (LBA) have dominated this area. However, the use of mass spectrometry in this ... now necessitates the question “How do you choose which approach to use (LBA or ...
(Date:6/19/2020)... ... ... The director of stem cell biotechnology company Asymmetrex , Dr. James L. ... have easier access to stem cell counting, they will soon make it a routine ... weekend in the U.S., Asymmetrex is offering free tissue stem cell counting at its ...
Breaking Biology News(10 mins):